Short-term LDL cholesterol-lowering efficacy of plant stanol esters by Hallikainen, Maarit et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cardiovascular Disorders
BMC Cardiovascular Disorders  2002,  2 x Research article
Short-term LDL cholesterol-lowering efficacy of plant stanol esters
Maarit Hallikainen*1, Essi Sarkkinen1,2, Ingmar Wester3 and Matti Uusitupa1
Address: 1Department of Clinical Nutrition, University of Kuopio, Finland, 2FoodFiles Ltd., Kuopio, Finland and 3Raisio Benecol Ltd., Raisio, 
Finland
E-mail: Maarit Hallikainen* - Maarit.Hallikainen@uku.fi; Essi Sarkkinen - Essi.Sarkkinen@Foodfiles.com; 
Ingmar Wester - Ingmar.Wester@Raisiogroup.com; Matti Uusitupa - Matti.Uusitupa@uku.fi
*Corresponding author
Abstract
Background: The short-term cholesterol-lowering efficacy of plant stanol esters has been open
to debate, and the data from different clinical studies with hypercholesterolemic subjects are
variable, partly due to lack of systematic studies. Therefore, we investigated the time in days needed
to obtain the full cholesterol-lowering effect of stanol esters in hypercholesterolemic subjects.
Methods: Eleven mildly to moderately hypercholesterolemic subjects consumed stanol ester
margarine (2.0 g/day of stanols) as a part of their habitual diet for 14 days and the changes in serum
lipid values were measured three times at 4, 8 and 15 days after the initiation of test margarine
consumption (0 day). The returning of serum lipid concentrations to baseline was measured two
times after 2 or 3 days and after 7 days of the end of the test margarine consumption.
Results: Serum LDL cholesterol concentrations were reduced from 0 day (4.51 ± 0.66 mmol/l) by
3.5% (P = ns), 9.9% (p < 0.05) and 10.2% (P < 0.05) at 4, 8 and 15 days, respectively. Serum
campesterol/total cholesterol ratio, an indirect marker of intestinal cholesterol absorption, was
significantly reduced on day 4 already. After ending the stanol ester use serum cholesterol
concentrations began to return rapidly and after 7 days serum LDL cholesterol was 5.3% less than
the initial value (P = ns).
Conclusion: The specific effect of plant stanol esters on serum LDL cholesterol can fully be
obtained within 1–2 weeks of the use of plant stanol ester-enriched margarine.
Background
Several clinical studies have shown that plant stanol esters
are effective cholesterol-lowering agents [1,2]. The choles-
terol-lowering effect of dietary plant stanol ester has been
shown to be sustained for periods up to 12 months [1],
but how soon full cholesterol-lowering effect of plant sta-
nol esters can be obtained, is still unclear. In most previ-
ous studies [3–5] the vast proportion of reduction in
serum cholesterol has been reported to occur within 2–3
weeks, but the effects of plant stanol esters probably ap-
pear sooner than that. The results from two clinical studies
with normo- or hypercholesterolemic subjects, where the
cholesterol measurements have also been done at time
point of one week, are conflicting: In one study [6], max-
imal cholesterol-lowering effect was obtained within a
week of dietary plant stanol ester use, whereas in the other
[7], no effect on serum cholesterol concentrations was ob-
tained after one week of dietary plant stanol ester use. On
the other hand, in a specific patient group, in colect-
omized patients [8], significant reduction in serum cho-
Published: 27 August 2002
BMC Cardiovascular Disorders 2002, 2:14
Received: 12 June 2002
Accepted: 27 August 2002
This article is available from: http://www.biomedcentral.com/1471-2261/2/14
© 2002 Hallikainen et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are per-
mitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/14
Page 2 of 7
(page number not for citation purposes)
lesterol was found already after one day of stanol ester use
as measured by gas liquid chromatograph (GLC), but a
steady state was reached just within one week. However,
as far as we know, short-term cholesterol-lowering effects
of plant stanol esters have not been studied at several re-
peated time points within short period of time in a real
target group for use of stanol ester-enriched products, i.e.
hypercholesterolemic subjects. Therefore, in the present
study our aim was to find out the time needed to obtain
the full cholesterol-lowering effect of plant stanol esters
with a daily dose of 2.0 g stanols in healthy, hypercholes-
terolemic subjects.
Methods
Subjects
Altogether 11 mildly to moderately hypercholesterolemic
(10 men and 1 women) subjects were recruited to the
study from subjects participated the former studies carried
out at the Department of Clinical Nutrition, University of
Kuopio. The main inclusion criteria were as follows: se-
rum total cholesterol 5.0–8.5 mmol/l and total triglycer-
ides below 2.5 mmol/l at screening. Other inclusion
criteria were aged 25–65 years, normal liver, kidney and
thyroid function, no lipid-lowering medication, no coro-
nary heart disease, no diabetes mellitus, no gastrointesti-
nal diseases, no alcohol abuse (>45 g of ethanol/d) and
no irregular eating habits. One subject used postmeno-
pausal estrogen therapy, one used a betablocker for the
treatment of hypertension and one used anti-thrombolyt-
ic medication. Two subjects were smokers. The subjects
were requested to keep their medication, weight, alcohol
consumption, smoking habits and physical activity con-
stant during the study. All 11 subjects completed the
study. Their mean age was 50.2 ± 8.8 y and mean body
mass index (BMI) was 27.0 ± 2.8 kg/m2. Baseline (0 day)
total, LDL, HDL and VLDL cholesterol and triglyceride
concentrations are shown in Table 2.
The subjects gave their informed consent for the study and
study protocol was approved by the Ethics Committee of
the Kuopio University Hospital.
Study design
The study was carried out at the Department of Clinical
Nutrition, University of Kuopio with the open and uncon-
trolled study design. The study lasted three weeks includ-
ing six visits to the study unit. Subjects started the study in
two batches so that one started a week later than the other
batch. For 14 days the subjects consumed the test marga-
rine daily and during this period the fasting blood sam-
ples were taken at the beginning of the experimental
period (0 day) and at days 4, 8 and 15 (meaning 3, 7 and
14 days after the initiation of test margarine consump-
tion, respectively). The returning of the serum lipid con-
centration was followed two times after 2 or 3 days (17 or
18 days) and after 7 days (22 days) from the end of the test
spread consumption.
At the first visit of the study (0 day) routine laboratory
measurements were taken to ensure normal health status.
In addition, medical history, use of drugs and nutrient
supplements, alcohol consumption, smoking habits and
physical activity were interviewed using a structured ques-
tionnaire. The possible changes in dietary habits, health
status and physical activity were asked to record in the fol-
low-up diary during the trial. The possible adverse effects
and symptoms were enquired based on a structured ques-
tionnaire at the end of the experimental period (15 days).
Diet
The subjects followed their habitual diet except replacing
25 g of their normal fat spread with rapeseed oil-based sta-
nol ester margarine daily (Benecol-80®, Raisio Group Plc,
Raisio, Finland). The fat content of test margarine was
72.5 %. Plant stanol esters were prepared from wood and
vegetable sterols (DRT, Les Derives Resiniques & Terpe-
niques Granel S.A. Dax Cedex, France and Archer Daniels
Midland Co, Decatur, IL, respectively) by recrystallization,
hydrogenation to form plant stanols, and esterification
with low-erucic acid rapeseed oil-based fatty acids to pro-
duce fatty acid esters of plant stanols. The margarine con-
tained 8.0 weight-% total stanols including 6.1 weight-%
sitostanol and 1.9 weight-% campestanol. Thus the target-
ed daily intake of total stanols based on the actual amount
of stanols in test spread was 2.0 g (1.52 g sitostanol and
0.47 g campestanol).
The subjects received the tubs of test margarine when vis-
iting the study unit. They were given detailed instructions
on how to use the test spread. Furthermore, the subjects
were asked to record the use of test spread daily and to re-
turn the empty and partly empty tubs and the extra tub of
test spread to the study unit at the end of experimental pe-
riod. The packages and the test spread left over were
weighed and the result recorded.
The background diet of the subjects was monitored by sev-
en-day food record (five weekdays and two weekend days)
and nutrient intake was calculated from the records by us-
ing the Micro-Nutrica® dietary analysis program (version
2.0, Finnish Social Insurance Institute, Turku, Finland).
The subjects kept the food record after the third study vis-
it.
Laboratory measurements
All measurements were done and venous blood samples
were obtained after 12-h overnight fast by using standard-
ized methods. Body weight was measured with a digital
scale.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/14
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Lipoproteins were separated by ultrasentrifugation for 18
h at density 1.006 to remove very low density lipoprotein
(VLDL). HDL in the infranatant was separated from LDL
by precipitation of LDL with dextran sulfate and magnesi-
um chloride [9]. LDL cholesterol was calculated as the dif-
ference between the mass of cholesterol in the infranatant
and HDL, and VLDL cholesterol was calculated as differ-
ence between the whole serum and the infranatant. Enzy-
matic photometric methods were used for the
determination of cholesterol and triglycerides from whole
serum and separated lipoproteins using commercial kits
(Monotest® Cholesterol and Triglyceride GPO-PAP, Boe-
hringer Mannheim GmbH Diagnostica, Mannheim, Ger-
many) with a Kone Specific Clinical Analyser (Kone Ltd.,
Espoo, Finland). The coefficients of variation between
measurements for serum total cholesterol were 1.4–1.7%,
for triglycerides were 2.1–2.2%, for HDL cholesterol were
0.4–1.4% and for HDL triglycerides was 0.8%.
Serum cholesterol precursors, cholestanol and plant ster-
ols were measured by GLC (HP 5890 Series II, Hewlett
Packard, Delaware, Little Falls, USA) from nonsaponifia-
ble serum material [10,11] equipped with a 50-m long Ul-
tra 1 capillary column (Methyl-polysiloxane) (Hewlett
Packard, Delaware, Little Falls, USA) for cholestanol, des-
mosterol, squalene, 8∆ -cholestenol, 7∆ -lathosterol,
campesterol and sitosterol, and equipped with a 50-m
long Ultra 2 capillary column (5 % Phenyl-methyl si-
loxane) (Hewlett Packard, Delaware, Little Falls, USA) for
sitostanol and campestanol. 5α -cholestanol for cholester-
ol and epi-coprostanol for cholesterol precursors, plant
sterols and cholestanol were used as internal standards.
Serum cholesterol precursors, cholestanol and plant ster-
ols were determined twice and the mean value of two
measurements was used in the statistical analysis. To elim-
inate the effects of the impact of changes in the amount of
sterol transporting lipoprotein particles, values of above-
mentioned variables are presented in terms of 10-2mg/mg
of cholesterol (GLC), which express ratio to total choles-
terol.
Plasma glucose was analyzed by enzymatic photometric
method using reagent Granutest 100 (Merck, Damstadt,
Germany) with a Kone Specific Clinical Analyser (Kone
Ltd., Espoo, Finland).
Statistical analyses
All statistical analyses were performed with SPSS for win-
dows 6.0.1 statistics program (SPSS, Chicago, IL, USA)
[12]. The results are given as means ± SDs and in some
cases also as  range. Normal distribution of variables was
checked with Shapiro Wilks test before the further analy-
ses. If a variable was not normally distributed statistical
analysis was made after logarithmic transformation. Sim-
ple factorial analysis of variance (ANOVA) was used to test
whether there were differences in the initial measure-
ments of each period (0 day and 15 days) between two
starting batches. Analysis of variance for repeated meas-
urements (MANOVA) was used to compare the overall
changes in continuous variables among different dose pe-
riods. Two-tailed comparisons with paired t-test were used
in the further analyses. For variables which were not nor-
mally distributed not even after logarithmic transforma-
tion Friedman Two-tailed ANOVA test or Wilcoxon
matched-paired signed rank test or Mann-Whitney test
was used. To control the overall level Bonferroni adjust-
ment was used.
Results
Baseline Characteristics
During the experimental period BMI decreased <1%, from
27.0 ± 2.8 to 26.7 ± 2.7 kg/m2 (P < 0.01), whereas during
the follow-up period BMI remained unchanged. Because
the change of BMI was significant during the experimental
period, the analyses of that period were made both with
and without BMI as covariate. Medication, physical activ-
ity and smoking habits remained stable. No side effects
were found during the experimental period.
Feasibility of the diet
The intake of nutrients of background diet during the ex-
perimental period are presented in Table 1. The mean dai-
ly consumption of margarine according to the weighed
returned tubs was 25.4 ± 0.8 g (24.4–27.5 g). Thus the ac-
tual daily intake of stanol was 2.03 ± 0.06 g (1.54 ± 0.05
g sitostanol and 0.48 ± 0.02 g campestanol).
Table 1: Daily intake of energy and nutrients during the study.
Nutrients Habitual diet
Energy (kcal) 2112 ± 507
Fat (% of energy) 33.3 ± 3.4
Saturated fatty acids (% of energy) 11.2 ± 1.5
Monounsaturated fatty acids (% of energy) 13.0 ± 1.8
Polyunsaturated fatty acids (% of energy) 6.4 ± 0.9
Proteins (% of energy) 15.7 ± 1.8
Carbohydrates (% of energy) 45.4 ± 5.6
Alcohol (% of energy) 4.3 ± 3.6
Cholesterol (mg) 219 ± 67
Fiber (g) 24.5 ± 6.7
Vitamin A (µg RE/day)1 977 ± 550
β -carotene (µg/day) 2901 ± 2685
Vitamin D (µg/day) 5.6 ± 2.5
Vitamin E (mg/day) 12.3 ± 1.5
Values are means ± SD, n = 11 1 RE = retinol equivalentsBMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/14
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Serum lipids and lipoproteins
Serum lipid and lipoprotein concentrations are presented
in Table 2.
No significant differences were found in the mean values
of serum lipids and lipoproteins at 0 and 15 days between
the two starting batches. Furthermore, though the first fol-
low-up blood sample was taken from first batch the day
before (17 day) than from the second batch (18 day), no
significant differences were found in serum lipids and li-
poprotein concentrations in the first follow-up sample be-
tween the two starting batches.
During the experimental period serum LDL cholesterol
concentration decreased slightly already at 4 days, but the
decrease was not significant until at 8 days (Table 2). In
addition, no further decrease in serum LDL cholesterol
concentration was found from the 8 to 15 days. At the
time points 8 and 15 days the decrease of serum LDL cho-
lesterol was significant even when the changes in BMI
were taken into account in the analysis as covariate (P =
0.012–0.051). The reductions in serum total cholesterol
paralleled the reductions in serum LDL cholesterol except
at 15 days due to the significant increase of VLDL choles-
terol. There were no significant changes in serum HDL
cholesterol and triglyceride concentrations during the ex-
perimental period (Table 2).
During the follow-up period serum total and LDL choles-
terol concentrations began to return immediately after ter-
mination of test spread consumption, but the changes
were significant neither at 17/18 days nor at 22 days. At 22
days serum LDL cholesterol concentration was still 5.3 ±
10.0 % lower than the initial value (0 day).
Plant sterols and cholesterol precursors
The results of serum plant sterols, cholestanol and choles-
terol precursors are shown in Table 3. There were signifi-
cant differences in the mean values of serum sitosterol at
the 0 and 15 days between the two starting batches, there-
fore the initial values were taken into account in the anal-
yses as a covariate.
Serum plant sterols, and in particular serum campesterol/
total cholesterol ratio, which reflects cholesterol absorp-
tion efficacy [13–15], reduced significantly already at 4
days (Table 3). In contrast, the ratios of serum campesta-
nol and sitostanol to total cholesterol increased signifi-
cantly during the experimental period and the significant
increase was reached in 4 days. However, after termina-
tion of test spread consumption serum campestanol and
sitostanol decreased rapidly and the reduction was signif-
icant already at 17/18 days. At 22 days serum campesta-
nol/total cholesterol ratio had almost returned to baseline
(P = 0.614), but sitostanol/total cholesterol ratio was
slightly, but still significantly, greater than baseline (P =
0.033).
Serum 7∆ -lathosterol/total cholesterol ratio, which re-
flects cholesterol synthesis [13,14,16], increased during
the experimental period and the increase was statistically
significant at 15 days compared with the initial value (Ta-
ble 3).
Table 2: Serum lipids and lipoproteins (mmol/l) during the study.
Experimental period Follow-up period
0 day 4 days 8 days 15 days 17 or 18 days 22 days P1 P2
Total cholesterol 6.33 ± 0.64 6.16 ± 0.74 5.81 ± 0.76a 6.06 ± 0.83 6.16 ± 0.75 6.30 ± 0.87 0.014 0.316
LDL cholesterol 4.51 ± 0.66 4.34 ± 0.69 4.06 ± 0.75a 4.04 ± 0.68a 4.21 ± 0.67 4.26 ± 0.72 0.001 0.183
HDL cholesterol 1.36 ± 0.31 1.34 ± 0.31 1.31 ± 0.30 1.36 ± 0.30 1.35 ± 0.34 1.37 ± 0.35 0.247 0.935
VLDL cholesterol 0.47 ± 0.26 0.48 ± 0.22 0.44 ± 0.27 0.67 ± 0.21a 0.60 ± 0.18 0.66 ± 0.54 0.011 0.811
Triglycerides 1.61 ± 0.54 1.41 ± 0.55 1.40 ± 0.57 1.61 ± 0.59 1.47 ± 0.46 1.90 ± 1.04 0.311 0.236
Values are means ± SD, n = 11. 1 indicate the significance of the differences for overall changes during the experimental period (days 0–15) analyzed 
with analysis of variance for repeated measurements (MANOVA). 2 indicate the significance of the differences for overall changes during the follow-
up period (days 15–22) analyzed with analysis of variance for repeated measurements (MANOVA). a p < 0.05 significantly different from the values 
of 0 day analyzed with paired t-test with Bonferroni correction.
Footnotes. During the experimental period the percentage changes (versus 0 day) in serum total cholesterol were -2.6 ± 8.1%, -8.2 ± 8.7% and -4.3 
± 8.1% at days 4, 8 and 15, respectively, and during the follow up period the changes were -2.7 ± 7.2% and -0.6 ± 8.8% at days 17/18 and 22, respec-
tively. Respective changes in serum LDL cholesterol were -3.5 ± 8.9%, -9.9 ± 10.4%, -10.2 ± 10.5%, -6.5 ± 8.7% and -5.3 ± 10.0%.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/14
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Discussion
The main results of the present study with hypercholeste-
rolemic subjects were that the significant decrease in se-
rum LDL cholesterol concentrations was achieved already
after one week of the initiation of stanol ester margarine
consumption, and that no additional cholesterol-lower-
ing effect was obtained between the 8th and 15th days (-
9.9% and -10.2%, respectively). Our findings agree with
the findings of Mensink et al. [6] in which full cholesterol-
lowering effect was reached within one week with stanol
ester use. These results are also in line with the values of
two weeks of our dose-response study, where serum LDL
cholesterol was reduced significantly by 10.5%, 11.2%,
17.4% and 17.4% versus control with the daily stanol
dose of 0.8 g, 1.6 g, 2.4 g and 3.2 g, respectively [17]. In
contrast to the above findings, Jones et al. [7] did not find
any effect on serum cholesterol concentrations after one
week with stanol ester use. It can be speculated that some
background factors, such as changes in diet, might have
confounded their results. In fact, the actual composition
of the diet has not been reported in that study. Our study
can be criticized because of the lack of the control group.
It is clear that the fatty acid modification contributes to
the serum cholesterol reduction, but this takes place after
a few week consumption. Therefore, the changes in serum
cholesterol concentrations in the present study can be as-
cribed to plant stanol ester use despite the lack of the con-
trol group. Furthermore, these results can be ascribed to
plant stanol ester use, since the compliance of subjects
was good according to the follow-up diaries and weighted
returned tubs. In addition, the changes in serum plant
sterol and stanol concentrations reveal the good compli-
ance. Moreover, our results are supported by results from
the studies of Mensink et al. [6] and Miettinen et al.[8].
In a specific patient group, in colectomized patients [8],
significant reduction in serum cholesterol concentrations
was reported already after one day of stanol ester con-
sumption. However, in the present study with hypercho-
lesterolemic subjects we found non-significant reduction
in serum cholesterol at 4 days. The different results could
be explained by different cholesterol metabolism between
the healthy subjects and colectomized patients. In colect-
omized patients transit time is very short, on an average
4–6 hours, and removal of cholesterol is slightly increased
[18,19]. Our result in noncolectomized hypercholestero-
lemic subjects is not unexpected, since under normal cir-
cumstances the half-life of disappearance of LDL apo B-
100 from the circulation is about 21/2 days, therefore se-
rum LDL cholesterol concentration can be expected to de-
crease significantly only after some days of stanol ester use
[20].
Serum VLDL cholesterol concentration was significantly
higher at 15 days compared with the initial value. Howev-
er, this finding was likely occasional and due to temporary
increased alcohol consumption – about 2% higher than
recorded in other studies – since plant stanols have gener-
Table 3: Ratios of serum cholesterol precursors and plant sterols to total cholesterol (10-2mg/mg of cholesterol) during the study.
Experimental period Follow-up period
0 day 4 days 8 days 15 days 17 or 18 days 22 days P1 P2
Squalene/TC 0.49 ± 0.12 0.46 ± 0.14 0.55 ± 0.20 0.51± 0.12 0.46 ± 0.14 0.48 ± 0.20 0.390 0.662
∆ 8-cholestenol/TC 0.22 ± 0.09 0.22 ± 0.09 0.24 ± 0.06 0.25 ± 0.08 0.24 ± 0.07 0.23 ± 0.07 0.101 0.280
∆ 7-lathosterol/TC 1.67 ± 0.58 1.75 ± 0.60 1.89 ± 0.34 1.98 ± 0.48a 1.86 ± 0.46 1.71 ± 0.45 0.012 0.116
Desmosterol/TC 1.05 ± 0.26 1.01 ± 0.18 1.09 ± 0.15 1.13 ± 0.14 1.04 ± 0.15b 1.06 ± 0.13 0.026 0.018
Campesterol/TC 2.86 ± 0.89 2.58 ± 0.81c 2.38 ± 0.69a 2.14 ± 0.58c 2.44 ± 0.59d 2.57 ± 0.65e 0.001 <0.001
Sitosterol/TC 1.42 ± 0.50 1.28 ± 0.45a 1.16 ± 0.38c 1.04 ± 0.34c 1.17 ± 0.36d 1.28 ± 0.39d 0.004* <0.001*
Avenasterol/TC 0.49 ± 0.13 0.44 ± 0.12f 0.45 ± 0.11 0.42 ± 0.07f 0.44 ± 0.10 0.44 ± 0.12 0.013 0.336
Campestanol/TC 0.02 ± 0.08 0.04 ± 0.02f 0.07 ± 0.03c 0.07 ± 0.02c 0.05 ± 0.02b 0.03 ± 0.09d <0.001 <0.001
Sitostanol/TC 0.08 ± 0.04 0.13 ± 0.07a 0.16 ± 0.05c 0.18 ± 0.04c 0.15 ± 0.04e 0.12 ± 0.04d <0.001 <0.001
Cholestanol/TC 1.32 ± 0.26 1.30 ± 0.27 1.39 ± 0.24 1.30 ± 0.23 1.32 ± 0.28 1.31 ± 0.28 0.185 0.517
Values are means ± SD, n = 11. TC = total cholesterol 1 indicates the significance of the differences for overall changes during the experimental 
period (days 0–15) 2 indicates the significance of the differences for overall changes during the follow-up period (days 15–22) analyzed with analysis 
of variance for repeated measurements (MANOVA) or Friedman Two-way ANOVA test (Avenasterol/TC). * Initial concentration (0 day or 15 
days) was significantly different by ANOVA between the two starting batches; therefore, the initial concentration was taken into account in the anal-
yses as a covariate. a P < 0.01, c P < 0.001, f P < 0.05 significantly different from the values of 0 day analyzed with paired t-test or Wilcoxon matched-
paired test with Bonferroni correction. b P < 0.05, d P < 0.001, e P < 0.01 significantly different from the values of 15 days analyzed with paired t-test 
with Bonferroni correction.BMC Cardiovascular Disorders 2002, 2 http://www.biomedcentral.com/1471-2261/2/14
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ally not been reported to affect serum VLDL cholesterol
[21–26].
Hypocholesterolemic effect of plant stanol esters is based
on their ability to inhibit cholesterol absorption effective-
ly from small intestine [27]. Serum campesterol/total cho-
lesterol ratio has been found to be an indirect marker of
cholesterol absorption [13–15]. In the present study, se-
rum campesterol/total cholesterol ratio decreased signifi-
cantly already within 4 days indicating that intestinal
cholesterol absorption reduces rapidly after the initiation
of the stanol ester consumption. This support the finding
that cholesterol-lowering effect of stanol esters appears
very soon after the initiation of their consumption. On
the other hand, during the experimental period serum 7∆ -
lathosterol/cholesterol ratio [13,14,16] increased signifi-
cantly reflecting the enhanced endogenous cholesterol
synthesis as a feedback reaction to the reduced cholesterol
absorption. Also in previous studies the synthesis of ∆ 7-
lathosterol has been found to be stimulated by plant sta-
nol esters [22,23,28–31]. In fact, Relas et al. [32] suggest-
ed that effectively increased endogenous cholesterol
synthesis was a reason for the inconsistent decrease in se-
rum total and LDL cholesterol after 2 weeks with stanol
ester use in their study.
Similar to recent stanol ester studies [3,8,26,31,33–35], in
the present study sitostanol and campestanol from stanol
ester margarine seemed to be absorbed to some extent.
However, the rapid reduction in serum plant stanol con-
centration after termination of the test margarine con-
sumption, indicates that biliary elimination of plant
stanols is rapid and that they are not stored in the human
body.
During the follow-up period the returning of serum cho-
lesterol to the initial values began rapidly after termina-
tion of the consumption of plant stanol esters. However,
after one week serum LDL cholesterol value was still 5%
lower than the initial value indicating that full return to
the initial values after use of the plant stanol ester en-
riched-margarine does not take place within one week.
This finding supports the finding of previous studies
[1,3,6] in which the returning to baseline has been found
to occur after two to three weeks of the termination.
Therefore, consumption of products enriched with stanol
esters should be regular in order to receive sustainable
cholesterol-lowering effect. In addition to that it should
be taken into account that although clinically significant
benefit can be reached already within one week with the
plant stanol ester use, a steady state in serum cholesterol
concentrations is usually attained within 3–4 weeks.
Therefore, serum cholesterol values are reasonable to fol-
low at least that time, especially if there is need to match
cholesterol-lowering drug therapy with the use of dietary
plant stanol esters.
Conclusions
In conclusion, effect of plant stanol esters on serum LDL
cholesterol concentrations can fully be obtained within
1–2 weeks of the use of plant stanol ester-enriched marga-
rine in hypercholesterolemic subjects.
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